Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1980 1
1981 2
1982 1
1983 3
1985 1
1987 1
1989 1
1990 1
1991 1
1992 4
1993 1
1994 2
1995 4
1996 3
1997 4
1998 7
1999 12
2000 13
2001 14
2002 12
2003 20
2004 25
2005 24
2006 34
2007 54
2008 34
2009 56
2010 52
2011 64
2012 52
2013 54
2014 60
2015 58
2016 54
2017 52
2018 54
2019 44
2020 47
2021 58
2022 57
2023 49
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

986 results

Results by year

Filters applied: . Clear all
Page 1
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Kopetz S, et al. Among authors: hong ys. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566309 Clinical Trial.
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Tabernero J, et al. Among authors: hong ys. J Clin Oncol. 2021 Feb 1;39(4):273-284. doi: 10.1200/JCO.20.02088. J Clin Oncol. 2021. PMID: 33503393 Free PMC article. Clinical Trial.
Deleterious heteroplasmic mitochondrial mutations are associated with an increased risk of overall and cancer-specific mortality.
Hong YS, Battle SL, Shi W, Puiu D, Pillalamarri V, Xie J, Pankratz N, Lake NJ, Lek M, Rotter JI, Rich SS, Kooperberg C, Reiner AP, Auer PL, Heard-Costa N, Liu C, Lai M, Murabito JM, Levy D, Grove ML, Alonso A, Gibbs R, Dugan-Perez S, Gondek LP, Guallar E, Arking DE. Hong YS, et al. Nat Commun. 2023 Sep 30;14(1):6113. doi: 10.1038/s41467-023-41785-7. Nat Commun. 2023. PMID: 37777527 Free PMC article.
Evaluation and management of lead exposure.
Kim HC, Jang TW, Chae HJ, Choi WJ, Ha MN, Ye BJ, Kim BG, Jeon MJ, Kim SY, Hong YS. Kim HC, et al. Among authors: hong ys. Ann Occup Environ Med. 2015 Dec 15;27:30. doi: 10.1186/s40557-015-0085-9. eCollection 2015. Ann Occup Environ Med. 2015. PMID: 26677413 Free PMC article. Review.
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Among authors: hong ys. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.
Rare Cause of Exertional Angina.
Seo KW, Hong YS, Park JS. Seo KW, et al. Among authors: hong ys. J Korean Med Sci. 2023 Dec 25;38(50):e421. doi: 10.3346/jkms.2023.38.e421. J Korean Med Sci. 2023. PMID: 38147842 Free PMC article. No abstract available.
Causal inference in environmental epidemiology.
Bae S, Kim HC, Ye B, Choi WJ, Hong YS, Ha M. Bae S, et al. Among authors: hong ys. Environ Health Toxicol. 2017 Oct 7;32:e2017015. doi: 10.5620/eht.e2017015. eCollection 2017. Environ Health Toxicol. 2017. PMID: 29026062 Free PMC article.
Nigral MRI features of asymptomatic welders.
Lee EY, Flynn MR, Du G, Lewis MM, Goldenberg M, Kong L, Mailman RB, Hong YS, Huang X. Lee EY, et al. Among authors: hong ys. Parkinsonism Relat Disord. 2021 Apr;85:37-43. doi: 10.1016/j.parkreldis.2021.02.020. Epub 2021 Feb 24. Parkinsonism Relat Disord. 2021. PMID: 33691274 Free PMC article.
Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis.
Hyung J, Lee JY, Kim JE, Yoon S, Yoo C, Hong YS, Jeong JH, Kim TW, Jeon S, Jun HR, Jung CK, Jang JP, Kim J, Chun SM, Ahn JH. Hyung J, et al. Among authors: hong ys. ESMO Open. 2023 Jun;8(3):101583. doi: 10.1016/j.esmoop.2023.101583. Epub 2023 Jun 14. ESMO Open. 2023. PMID: 37327700 Free PMC article. Clinical Trial.
986 results